Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product PYLARIFY and its competitive position during the specified class period from February 26, 2025, to August 5, 2025 [1][2]. Allegations of Misconduct - The lawsuit claims that Lantheus misled investors about PYLARIFY's competitive position, failing to properly assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing PYLARIFY's price point and revenue potential [2]. - The complaint asserts that the public statements made by Lantheus were materially false and misleading throughout the class period [2]. Lead Plaintiff Process - Investors in Lantheus have until November 10, 2025, to seek appointment as a lead plaintiff representative in the class action [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm encourages Lantheus investors who have suffered losses to contact them for more information [4].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook during the specified class period from May 7, 2025, to August 5, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC on behalf of investors who acquired LifeMD shares during the class period [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against LifeMD - LifeMD is accused of overstating its competitive position and raising its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs like Wegovy and Zepbound [3]. - Following the revelation of the true facts, LifeMD's shares experienced a significant decline of 44%, equating to a drop of $5.31 per share in a single trading session [3].

, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of KinderCare Learning Companies, Inc. (NYSE: KLC) common stock in or traceable to KinderCare's October 2024 initial public offering (the "IPO"), have until Monday, October 13, 2025 to seek appointment as lead plaintiff of the KinderCare class action lawsuit. Captioned Gollapalli v. KinderCare Learning Companies, Inc., No. 25-cv-01424 (D. Or.), the KinderCare class action lawsuit charges KinderCare and certain of Ki ...

, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Charter Communications, Inc. ("Charter") (NASDAQ: CHTR) on behalf of those who purchased or otherwise acquired Charter securities, including purchasers of call options, or sellers of put options, between July 26, 2024, and July 24, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is October 14, 2025. CONTACT KESSLER TOPAZ MELTZE ...

Core Viewpoint - A lawsuit has been filed against Charter Communications, Inc. and certain senior executives for potential violations of federal securities laws, particularly related to the impact of the Affordable Connectivity Program's termination on the company's customer base and earnings [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Sandoval v. Charter Communications, Inc., No. 1:25-cv-06747, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until October 14, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Charter is a leading broadband and cable operator that participated in the FCC's Affordable Connectivity Program (ACP), which provided funding to subsidize high-speed internet plans for low-income households [3]. - The ACP ended in June 2024 due to a lack of federal funding, leading to customer declines for Charter [3]. Group 3: Financial Impact - During the relevant period, Charter claimed to have successfully managed the risks associated with the end of the ACP, stating that the impact was behind them [4]. - However, the company continued to experience declines in internet customers and revenue, contradicting its earlier statements [4]. Group 4: Stock Performance - Following the announcement of its second quarter 2025 financial results on July 25, 2025, Charter reported a decrease of 117,000 total internet customers, including approximately 50,000 disconnects related to the ACP's end, nearly double from the previous quarter [5]. - The stock price fell by $70.25 per share, or 18.4%, from $380.00 on July 24, 2025, to $309.75 on July 25, 2025, reflecting the negative market reaction to the news [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of Spirit Aviation Holdings, Inc. during the specified class period, highlighting potential financial misrepresentations by the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit is aimed at purchasers of Spirit Aviation securities between May 28, 2025, and August 29, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by December 1, 2025, to represent other class members in the litigation [3]. Group 2: Allegations Against Spirit Aviation - The complaint alleges that Spirit Aviation was at significant risk of failing to meet its debt obligations and may have to file for Chapter 11 bankruptcy protection within months [5]. - It is claimed that the defendants overstated the company's financial condition and liquidity while downplaying adverse market conditions [5]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, leading to investor damages when the true situation was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - The Molina Healthcare class action lawsuit alleges that the company and its executives violated the Securities Exchange Act of 1934 by failing to disclose critical information regarding financial performance and medical cost trends during the specified class period [1][3]. Group 1: Lawsuit Details - The class action lawsuit seeks to represent purchasers or acquirers of Molina Healthcare securities from February 5, 2025, to July 23, 2025 [1]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., No. 25-cv-09461 (C.D. Cal.) [1]. - Allegations include failure to disclose adverse facts about medical cost trend assumptions and a dislocation between premium rates and medical costs [3]. Group 2: Financial Performance - On July 7, 2025, Molina Healthcare reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2% at the midpoint, citing ongoing medical cost pressures [4]. - On July 23, 2025, Molina Healthcare reported GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year over year, and revised its full-year 2025 adjusted earnings expectation to no less than $19.00 per diluted share [5]. Group 3: Market Reaction - Following the earnings report on July 7, 2025, Molina Healthcare's stock price fell significantly, reflecting investor concerns over the disclosed medical cost pressures [4]. - After the July 23, 2025 report, the stock price dropped nearly 17%, indicating a strong negative market reaction to the revised earnings guidance [5].

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ:NUTX) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until October 21, 2025 to ask the Court to appoint them as lead plaintiff. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened? O ...

, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Dow Inc. (NYSE: DOW) securities between January 30, 2025 and July 23, 2025, all dates inclusive (the "Class Period"), have until Tuesday, October 28, 2025 to seek appointment as lead plaintiff of the Dow class action lawsuit. Captioned Sarti v. Dow Inc., No. 25-cv-12744 (E.D. Mich.), the Dow class action lawsuit charges Dow, The Dow Chemical Company, a Dow subsidiary, as well as certain of Dow's exec ...

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Firefly Aerospace Inc. (NASDAQ: FLY) focused on whether Firefly Aerospace as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Firefly Aerospace investigation or if you are a Firefly Aerospace investor who suffered a ...